Explore an Evidence-Based

Medical Learning Journey

This medical learning journey is an opportunity to engage in a unique in-depth educational experience designed for healthcare providers to learn more about Tafamidis mechanism of action in ATTR-CM, the relationship of binding-site occupancy, transthyretin stabilization, and disease modifying effect.

ATTR cardiac amyloidosis (ATTR-CM) is an underdiagnosed, progressive, and infiltrative disease that is often overlooked as a cause of heart failure.^1-3 Untreated patients with ATTR-CM have a median survival of ~2-6 years after diagnosis.

Tafamidis is a selective stabilizer that inhibits the dissociation of TTR to preserve its natural function. A recent study demonstrated that the clinically approved dose of 80 mg tafamidis meglumine achieves a near-maximum^* (>90%) effect on both TTR stabilization and disease-relevant measures.¹⁰

To begin, please click the button below.